By Money Morning News Team, Money Morning - • Print | Email
Since hitting a high in late January, the iShares Nasdaq Biotechnology ETF has slumped more than 11%. But that doesn't mean investors should stop looking for the best biotech stocks to buy today.
You see, the slump in biotech stocks has little to do with their true worth.
In fact, some of the best biotech stocks are currently trading well below their fundamental value, according to their earnings and assets.
Here are the three best biotech stocks to buy now, while they're still on sale...
By Money Morning Staff Reports, Money Morning - • Print | Email
Biotech stocks have already netted investors huge gains.
In fact, we expect prices to skyrocket even further as the industry becomes a $727 billion juggernaut.
By Stephen Mack, Associate Editor, Money Morning - • Print | Email
Biotech stocks have been getting hit hard in early 2018, but it's largely because of market overreactions to minor setbacks and rumors.
Based on earnings and assets, some biotech stocks are now available at remarkable discounts.
We've got three picks that are ready to break out in a big way.
By Michael A. Robinson, Defense + Tech Specialist, Money Morning • @Robinson_STI - • Print | Email
When it comes to biotech, Wall Street tends to overreact. Though there's no reason for it to be there, biotech is in the dog house, and investors have been conditioned to punish the sector and its stocks whenever the opportunity presents itself.
You see, there are three main reasons biotech is down: Wall Street is worried about high and rising drug prices, the impact of a possible trade war on foreign sales, and expiring patents for some older medications.
Over the last several years, for example, I've read a number of Wall Street reports about the so-called "biotech patent cliff." Simply stated, a drug falls off that "cliff" when its patent runs out and it starts facing competition from generics.
And a number of successful drugs out there are rapidly approaching their patent cliffs.
That sounds bad.
But there are good things happening in biotech, as well. In fact, what you don't hear much about is that the industry is about to bust out.
For example, I was thrilled to see a recent report from Clarivant Analytics, a research firm that works closely with industry leaders and top universities, which says a total of 12 compounds being released in 2018 could become blockbusters.
So I went through the data and found one ultimate biotech blockbuster that I think could lead the pack.
By A.J. Bursick, Associate Editor, Money Morning - • Print | Email
Billionaire entrepreneur Mark Cuban invested in a small biotech company that will revolutionize the way doctors approach chest pains.
Of course, average investors don't have the ability to invest in such companies pre-IPO.
By Money Morning News Team, Money Morning - • Print | Email
You wouldn't know it from following mass media and Wall Street, but the stocks handing out the largest profits right now are in the biotechnology industry.
In fact, one of our three best biotech penny stocks to buy for March is a company developing treatments for the gut health of race horses, among other things.
All it takes is the announcement of positive clinical trial results to send this stock soaring...
By Money Morning News Team, Money Morning - • Print | Email
Investors looking for profits in the healthcare sector had a difficult time in 2017 if they weren't in biotech. The Health Care SPDR ETF only gained 13.15% last year, while the S&P 500 climbed 22.5% over the same time period.
But within the broader health care sector the SPDR S&P Biotech ETF returned a market-beating 43.36% in 2017, nearly double the broader S&P 500.
That's why today we'll show you the three best biotech stocks to buy for 2018.
By Money Morning Staff Reports, Money Morning - • Print | Email
Biotech stocks were among 2017's best performers, until news broke in October that congressional Republicans ditched efforts to repeal and replace Obamacare.
While the rest of the market was still soaring, the Wall Street herd simply turned its attention elsewhere – but that was a big mistake.
By Money Morning Staff Reports, Money Morning - • Print | Email
Right now, there's a major shift underway in the biotech field that's creating a brand-new $59.2 billion industry.
And investors who get in now could be positioning themselves for triple- or even quadruple-digit gains…
That's why we're bringing readers one of the best biotech stocks to buy in December 2017...
By Money Morning Staff Reports, Money Morning - • Print | Email
Healthcare spending is expected to soar through 2025 to make up 20% of total GDP.
Meanwhile, the massive baby boomer generation will likely be getting old by that year.
To profit from both trends, you should invest in this biotech stock today...
